Guggenheim downgraded Myriad Genetics (MYGN) to Neutral from Buy without a price target Based on key opinion leader checks on GeneSight and Prolaris, the firm cut estimates for both GeneSight and Prolaris. The analyst cites price compression for Genesight and lower Prolaris volume growth due to competitive pressures for the downgrade. Prolaris is losing market share in prostate cancer risk stratification and will not continue to grow in the foreseeable future, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics appoints Brian Donnelly as CCO
- Myriad Genetics price target lowered to $20 from $24 at Scotiabank
- Buy Rating on Myriad Genetics: Strategic Changes and Growth Potential Amid Challenges
- Myriad Genetics upgraded to Overweight from Neutral at Piper Sandler
- Myriad Genetics price target lowered to $16 from $21 at Morgan Stanley